Music & MEmory: A Pragmatic TRial for Nursing Home Residents With ALzheimer's Disease_part1 (METRIcAL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03821844 |
Recruitment Status :
Completed
First Posted : January 30, 2019
Last Update Posted : March 4, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dementia | Behavioral: Music and Memory | Not Applicable |
The purpose of this study is to conduct a parallel, pragmatic, cluster randomized control trial of personalized music (Music and Memory) for nursing home residents with moderate to severe dementia living in 54 nursing homes (27 treatment, 27 control) from 4 nursing home corporations. Music and Memory is a personalized music program that uses portable music players to deliver individualized music to people with dementia at times when agitated behaviors are likely.
**This funding mechanism sponsored two parallel trials with different implementation strategies. In this trial, nursing home staff identify the music a resident with dementia may have preferred when s/he was young by asking family members and testing individual songs with the resident. Details of the second parallel trial conducted under this funding mechanism are registered under "R33AG057451_part2."**
The aims of this study are: 1. To use a train-the-trainer model to implement the intervention with ongoing monitoring of the program's adoption and acceptance by nursing home residents with dementia; 2. To estimate the impact of Music and Memory on agitated and aggressive behaviors; and 3. To examine factors associated with variation in providers' adherence to the implementation of Music and Memory.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 976 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The investigator's primary outcome (staff report of resident agitated and aggressive behaviors) will be evaluated using a parallel design. Some secondary outcomes will be tested with a stepped wedge design. |
Masking: | Single (Investigator) |
Masking Description: | The principal investigator is blinded to random assignment of nursing homes to treatment or control conditions |
Primary Purpose: | Supportive Care |
Official Title: | Music & MEmory: A Pragmatic TRial for Nursing Home Residents With ALzheimer's Disease_part1 |
Actual Study Start Date : | May 1, 2019 |
Actual Primary Completion Date : | August 1, 2021 |
Actual Study Completion Date : | December 31, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Music and Memory
Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
|
Behavioral: Music and Memory
Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences. |
No Intervention: Usual Care
Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
|
- Frequency of agitated and aggressive behaviors (staff report) [ Time Frame: 4-months ]The tool used to interview staff about resident behaviors is the Cohen-Mansfield Agitation Inventory. Research staff interview a nursing staff member who knows the resident well to ask how frequently 29 agitated and/or aggressive behaviors occurred in the past week. There are seven response choices for each item, anchored from never (1) to several times per hour (7). Total scores on the Cohen-Mansfield Agitation Inventory range from 29 to 203, with higher scores representing more frequent agitated and/or aggressive behaviors. Mean overall scores will be compared for treatment and control populations.
- Frequency of agitated and aggressive behaviors (direct observation) [ Time Frame: 4-months ]The tool used to directly observe resident behaviors is the Agitation Behavior Mapping Instrument. Research staff observe residents for short intervals (3 minutes per observation) and record the number of times 14 specific verbally and physically agitated behaviors occurred (up to 10 times per observation). Total scores on the Agitation Behavior Mapping Instrument range from 0 to 140, with higher scores representing more agitated and/or aggressive behaviors. Mean total scores will be compared for treatment and control populations.
- Frequency of agitated and aggressive behaviors (administrative data) [ Time Frame: 4-months ]The Aggressive Behavior Scale is a 4-item measure describing the frequency of physical behavioral symptoms directed toward others; verbal behavioral symptoms directed toward others; other behavioral symptoms not directed toward others; and behaviors related to resisting necessary care. For each item, frequency in the past week is report as: behavior not exhibited (0); behavior occurred 1-3 days (1); behavior occurred 4-6 days (2); or behavior occurred daily (3). The Aggressive Behavior Scale ranges from 0 to 12, with higher scores indicating more frequent agitated and/or aggressive behaviors. Mean total scores will be compared for treatment and control populations.
- Antipsychotic use [ Time Frame: 4-months ]Any antipsychotic use in the past week and days of use in the past week, based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of percent with any use and mean days will be compared for treatment and control populations
- Antianxietal use [ Time Frame: 4-months ]Any antianxietal use in the past week and days of use in the past week, based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of percent with any use and mean days will be compared for treatment and control populations
- Antidepressant use [ Time Frame: 4-months ]Any antidepressant use in the past week and days of use in the past week, based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of percent with any use and mean days will be compared for treatment and control populations
- Hypnotic use [ Time Frame: 4-months ]Any hypnotic use in the past week and days of use in the past week, based on Minimum Data Set (standardized assessment of nursing home residents). Comparison of percent with any use and mean days will be compared for treatment and control populations
- Observed emotion [ Time Frame: 4-months ]The Observed Emotion Rating Scale is completed by a trained observer to document duration of five observed emotional states (pleasure, anger, anxiety / fear, sadness, and general alertness) during short observations (3 minutes per observation). For each emotional state, the researcher indicates whether or not the emotion was observed: never (1); less than 16 seconds (2); 16-59 seconds (3); 1-2 minutes (4); or 3+ minutes (5). Total scores range from 5 to 25, with higher scores indicating greater duration of observed emotion. Average observed emotion scores will be compared for treatment and control populations.
- Depression [ Time Frame: 4-months ]The Patient Health Questionnaire is a 9-item screening assessment for depression severity. For each item, respondents indicate the frequency of the symptom in the past 2 weeks using the following choices: never or one day (0); 2-6 days (1); 7-11 days (2); or 12-14 days (3). Total scores range from 0 to 27, with higher scores indicating more frequent depressive symptoms. Average total scores will be compared for treatment and control populations.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria for Nursing Homes:
- Owned by partnering health care corporations
- Medicare / Medicaid-certified
- Have at least 20 eligible residents
Inclusion Criteria for Residents in Eligible Nursing Homes
- Reside in eligible nursing home for last 90 days
- Have advanced dementia, defined by the presence of a dementia diagnosis and moderately or severely impaired daily decision-making
Exclusion Criteria for Nursing Homes:
- recent situations that may affect implementation (for example, bad state or federal quality assurance surveys, leadership turnover, or other competing demands)
- previous use of Music and Memory
Exclusion Criteria for Residents in Eligible Nursing Homes:
- dislikes music
- completely deaf

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03821844
United States, Georgia | |
PruittHealth | |
Norcross, Georgia, United States, 30093 | |
United States, Nebraska | |
Vetter Senior Living | |
Elkhorn, Nebraska, United States, 68022 | |
United States, Ohio | |
CommuniCare Terrapins Division | |
Blue Ash, Ohio, United States, 45241 | |
United States, South Dakota | |
Good Samaritan Society | |
Sioux Falls, South Dakota, United States, 57108 |
Principal Investigator: | Vincent Mor, PhD | Brown University, School of Public Health |
Responsible Party: | Vincent Mor, Florence Pirce Grant University Professor, Professor of Health Services, Policy and Practice, Brown University |
ClinicalTrials.gov Identifier: | NCT03821844 |
Other Study ID Numbers: |
R33AG057451_part1 R33AG057451 ( U.S. NIH Grant/Contract ) |
First Posted: | January 30, 2019 Key Record Dates |
Last Update Posted: | March 4, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |